- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03272542
PRebiotic to IMprovE Calcium Absorption (PRIME)
October 20, 2020 updated by: Anne Schafer, San Francisco Veterans Affairs Medical Center
Prebiotic Intervention to Improve Calcium Absorption After Gastric Bypass Surgery
Gastric bypass surgery is a highly effective treatment for obesity, but it has negative effects on skeletal health, due in part to a dramatic decline in intestinal calcium absorption capacity.
Animal and human studies suggest that non-digestible fibers termed prebiotics, such as soluble corn fiber (SCF), augment calcium absorption in the lower intestine as they act as substrates for beneficial gut microbiota.
This is a pilot randomized controlled trial of the effects of SCF vs. placebo on intestinal calcium absorption, bone turnover marker levels, and the gut microbiome in postmenopausal women who have previously undergone gastric bypass surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study is a pilot randomized control trial (RCT) of the effects of the prebiotic SCF vs. placebo in 20 postmenopausal women who underwent Roux-en-Y gastric bypass surgery 2-6 years previously and thus have completed the postoperative period of rapid weight loss and metabolic and dietary change.
A 24 g/day dose of SCF85 (which is approximately 20 g/day fiber) will be tested, as that dose was proven effective for calcium absorption/retention in healthy postmenopausal women and adolescents.
The SCF and the maltodextrin placebo will be mixed in water and consumed in divided doses twice daily for 2 months, a duration exceeding other SCF trials but remaining feasible for a pilot.
The primary outcome will be change in intestinal calcium absorption, which is the efficacy outcome about which the study must collect preliminary data and from which the investigators must refine power calculations for the anticipated future trial.
Because the investigators hypothesize that an increase in calcium absorption will decrease bone turnover and ultimately increase bone mineral density (BMD), the study will measure biochemical markers of bone turnover in this pilot.
Secondary outcomes will be gastrointestinal tolerability and acceptability.
On an exploratory basis, the study will determine effects of the prebiotic on the gut microbiome.
This pilot will yield critical experience about feasibility of recruitment and adherence to the intervention and measurements.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- UCSF
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Postmenopausal women (no menses for ≥4 yrs)
- ≤ 75 yrs old,
- Underwent Roux-en-Y gastric bypass surgery for weight loss 2-6 years prior
Exclusion Criteria:
- Serum 25(OH)vitamin D level <30 ng/mL (to remove the effect of vitamin D insufficiency/deficiency)*
- History of >1 bariatric surgical procedure
- Antibiotic therapy in the last 3 months
- Regular pre- or probiotic use in the last 3 months
- Regain of >50% of weight loss post-bypass
- Calculated creatinine clearance <30 mL/min
- Serum calcium >10.2 mg/dL
- Use of hormone therapy, osteoporosis pharmacotherapy, glucocorticoids, or other medications impacting calcium metabolism
- Thyroid stimulating hormone (TSH) <0.01 milli-international units per liter (mIU/L)
A potential participant may be excluded if she has a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
*Women excluded due to 25(OH)D level will be offered re-screening after vitamin D supplementation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prebiotic: soluble corn fiber
SCF (PromotorTM Soluble Corn Fiber 85, provided by manufacturer Tate & Lyle) will be dispensed to participants as a dry powder in sachets of 12 g SCF85 product (which is approximately 10 g fiber).
Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart.
(For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.)
Participants will be asked to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
|
prebiotic
Other Names:
|
Placebo Comparator: Placebo
The placebo control will be maltodextrin powder in identical sachets.
Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart.
(For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.)
Participants will be requested to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
|
placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in fractional intestinal calcium absorption
Time Frame: 2 months
|
Fractional calcium absorption to be determined using dual stable isotopic tracers
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in bone turnover markers
Time Frame: 2 months
|
Serum biochemical markers of bone turnover C-telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP)
|
2 months
|
Gastrointestinal tolerability
Time Frame: 2 months
|
Self-reported flatulence, bloating, abdominal pain, stomach noises
|
2 months
|
Acceptability
Time Frame: 2 months
|
Self-reported satisfaction, likelihood that one would be willing to consume the beverage for 12 months
|
2 months
|
Change in gut microbiome composition
Time Frame: 2 months
|
Stool bacterial and fungal composition to be analyzed, including alpha diversity and beta diversity metrics as well as taxon relative abundance, with subsequent in silico metagenomic predictions of enrichment of bacterial functional gene pathways
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Anne Schafer, MD, UCSF & SFVAMC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 21, 2017
Primary Completion (Actual)
January 31, 2020
Study Completion (Actual)
January 31, 2020
Study Registration Dates
First Submitted
August 25, 2017
First Submitted That Met QC Criteria
September 1, 2017
First Posted (Actual)
September 5, 2017
Study Record Updates
Last Update Posted (Actual)
October 22, 2020
Last Update Submitted That Met QC Criteria
October 20, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- 17-22618
- R21DK112126 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Prebiotic: soluble corn fiber
-
Purdue UniversityTate and Lyle Ingredients Americas LLCCompleted
-
Phoenix Children's HospitalMayo Clinic; Northern Arizona University; Flinn FoundationCompleted
-
University of Illinois at Urbana-ChampaignTate and Lyle Ingredients Americas LLCRecruiting
-
JeyaKumar HenryTate and Lyle Ingredients FranceCompletedObesity | Pre DiabetesSingapore
-
Purdue UniversityTate & Lyle Health & Nutrition SciencesCompletedOsteoporosis, Postmenopausal
-
University of MinnesotaTate and Lyle Ingredients FranceCompleted
-
University of ZagrebCroatian Science FoundationCompletedMicrobiota | Sports | Dietary Fiber | Nutrition Surveys | Sports NutritionCroatia
-
University of Illinois at Urbana-ChampaignCompleted